title: Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review.
abstract: Paclitaxel (PTX) and/or cisplatin (CDDP), as important cytotoxic anti-cancer agents, are widely used to treat various solid tumors. Both may cause moderate or severe neurotoxicity, but ocular neurotoxicity is also occasionally reported. A patient diagnosed with nasopharyngeal cancer suffering acute ocular neurotoxicity 10 days after paclitaxel and CDDP administration at the recommended dose is described in the present case report, and PTX- and/or CDDP-induced ocular neurotoxicity are summarized according to previous reports. Possible mechanisms and the potential diagnostic, therapeutic and predictive strategies of PTX- and/or CDDP-induced ocular neurotoxicity are reviewed, to help the oncologist to take the infrequent toxicity of cytotoxic drugs into account and improve patient safety during anti-cancer therapy.
authors.affiliation: Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan, People's Republic of China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan, People's Republic of China.
authors.forename: Yanping
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan, People's Republic of China.
authors.forename: Junyu
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan, People's Republic of China.
authors.forename: Guoliang
authors.initials: G
authors.lastname: Pi
authors.affiliation: Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan, People's Republic of China.
authors.forename: Wenyong
authors.initials: W
authors.lastname: Tan
keywords: CDDP; PTX; chemotherapy; cytotoxic drugs; oncology
references.citation: Arch Neurol. 1982 Nov;39(11):719-20
references.pmid: 6889850
references.citation: Arch Ophthalmol. 2007 May;125(5):709-10
references.pmid: 17502517
references.citation: Am J Ophthalmol. 2000 Sep;130(3):367-8
references.pmid: 11020424
references.citation: Am J Ophthalmol. 2006 Jan;141(1):196-7
references.pmid: 16387001
references.citation: Cutan Ocul Toxicol. 2014 Mar;33(1):7-10
references.pmid: 23638802
references.citation: Med Pediatr Oncol. 1998 Sep;31(3):177
references.pmid: 9722903
references.citation: J Clin Oncol. 1994 Aug;12(8):1741-2
references.pmid: 7913722
references.citation: J Neuroophthalmol. 1997 Sep;17(3):195-8
references.pmid: 9304534
references.citation: Cancer Treat Rev. 2014 Feb;40(1):197-203
references.pmid: 23850197
references.citation: Cancer. 1995 Mar 1;75(5):1141-50
references.pmid: 7850713
references.citation: J Clin Oncol. 1985 Dec;3(12):1683-9
references.pmid: 4067616
references.citation: Cancer. 1980 Feb 15;45(4):764-6
references.pmid: 7188878
references.citation: Cancer. 1995 Sep 1;76(5):916-7
references.pmid: 8625200
references.citation: J Neurooncol. 1995;25(3):221-5
references.pmid: 8592172
references.citation: J Neurooncol. 2006 Mar;77(1):79-87
references.pmid: 16132528
references.citation: Ann Oncol. 2002 Apr;13(4):629-31
references.pmid: 12056715
references.citation: J Neuroophthalmol. 2003 Jun;23(2):132-5
references.pmid: 12782925
references.citation: J Natl Cancer Inst. 1994 Jul 20;86(14):1099-101
references.pmid: 7912737
references.citation: Ophthalmic Surg Lasers Imaging Retina. 2013 Mar-Apr;44(2):183-6
references.pmid: 23429715
references.citation: Graefes Arch Clin Exp Ophthalmol. 2002 Dec;240(12):1033-5
references.pmid: 12483326
references.citation: Breast Cancer. 2004;11(1):82-5
references.pmid: 14718798
references.citation: Ann Oncol. 1997 Oct;8(10):1053
references.pmid: 9402182
references.citation: Onco Targets Ther. 2013 Nov 21;6:1719-28
references.pmid: 24311943
references.citation: Int Ophthalmol. 2012 Jun;32(3):299-304
references.pmid: 22484725